Literature DB >> 23197042

The predicated demise of racemic new molecular entities is an exaggeration.

Israel Agranat, Silvya R Wainschtein, Enav Z Zusman.   

Abstract

Mesh：

Year:  2012        PMID： 23197042     DOI： 10.1038/nrd3657-c1

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

Review 1.  Putting chirality to work: the strategy of chiral switches.

Authors:  Israel Agranat; Hava Caner; John Caldwell
Journal:  Nat Rev Drug Discov       Date:  2002-10       Impact factor: 84.694

2.  FDA's policy statement for the development of new stereoisomeric drugs.

Authors: 
Journal:  Chirality       Date:  1992       Impact factor: 2.437

Review 3.  Trends in the development of chiral drugs.

Authors:  Hava Caner; Efrat Groner; Liron Levy; Israel Agranat
Journal:  Drug Discov Today       Date:  2004-02-01       Impact factor: 7.851

4.  2011 FDA drug approvals.

Authors:  Asher Mullard
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

5.  The strategy of enantiomer patents of drugs.

Authors:  Israel Agranat; Silvya R Wainschtein
Journal:  Drug Discov Today       Date:  2010-01-29       Impact factor: 7.851

6.  Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology.

Authors:  E J Ariëns
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953
  6 in total
  11 in total

1.  Chiral Switch Drugs for Asthma and Allergies: True Benefit or Marketing Hype.

Authors:  Kathryn Blake; Hengameh Raissy
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2013-09       Impact factor: 1.349

2.  Learning epistatic interactions from sequence-activity data to predict enantioselectivity.

Authors:  Julian Zaugg; Yosephine Gumulya; Alpeshkumar K Malde; Mikael Bodén
Journal:  J Comput Aided Mol Des       Date:  2017-12-12       Impact factor: 3.686

3.  Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs.

Authors:  Vincent Jacques; Anthony W Czarnik; Thomas M Judge; Lex H T Van der Ploeg; Sheila H DeWitt
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-09       Impact factor: 11.205

4.  The Growing Importance of Chirality in 3D Chemical Space Exploration and Modern Drug Discovery Approaches for Hit-ID: Topical Innovations.

Authors:  Ilaria Proietti Silvestri; Paul J J Colbon
Journal:  ACS Med Chem Lett       Date:  2021-07-16       Impact factor: 4.632

5.  Mirror-Image Packing Provides a Molecular Basis for the Nanomolar Equipotency of Enantiomers of an Experimental Herbicide.

Authors:  Claudine Bisson; K Linda Britton; Svetlana E Sedelnikova; H Fiona Rodgers; Thomas C Eadsforth; Russell C Viner; Tim R Hawkes; Patrick J Baker; David W Rice
Journal:  Angew Chem Int Ed Engl       Date:  2016-09-26       Impact factor: 15.336

Review 6.  Asymmetric 18F-fluorination for applications in positron emission tomography.

Authors:  Faye Buckingham; Véronique Gouverneur
Journal:  Chem Sci       Date:  2015-12-17       Impact factor: 9.825

Review 7.  Significance and challenges of stereoselectivity assessing methods in drug metabolism.

Authors:  Zhuowei Shen; Chuang Lv; Su Zeng
Journal:  J Pharm Anal       Date:  2015-12-21

8.  Relative configuration of micrograms of natural compounds using proton residual chemical shift anisotropy.

Authors:  Nilamoni Nath; Juan Carlos Fuentes-Monteverde; Dawrin Pech-Puch; Jaime Rodríguez; Carlos Jiménez; Markus Noll; Alexander Kreiter; Michael Reggelin; Armando Navarro-Vázquez; Christian Griesinger
Journal:  Nat Commun       Date:  2020-09-01       Impact factor: 14.919

9.  Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.

Authors:  Ilaria D'Acquarica; Israel Agranat
Journal:  Drug Discov Today       Date:  2020-05-01       Impact factor: 7.851

10.  Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme.

Authors:  Geoffrey Masuyer; Mohd Akif; Bertrand Czarny; Fabrice Beau; Sylva L U Schwager; Edward D Sturrock; R Elwyn Isaac; Vincent Dive; K Ravi Acharya
Journal:  FEBS J       Date:  2013-12-24       Impact factor: 5.542
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.